SCHEMBL3789153

SCHEMBL3789153

FC(F)(F)c1ccc(Cl)cc1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.52
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
TMPRSS4 Q9NRS4 2/20 0.47
RAB9A P51151 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.41
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
PDK2 Q15119 1/20 0.39
HCAR1 Q9BXC0 1/20 0.38
POLQ O75417 1/20 0.38
PKM P14618 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11119102 0.93 CYP3A4 (0.58) CYP3A4TSHRMAPK1TDP1TMPRSS4
SCHEMBL803432 0.86 MAPK1 (0.45) CYP3A4TSHRMAPK1TDP1TMPRSS4
SCHEMBL803427 0.86 RAB9A (0.41) CYP3A4TSHRMAPK1TDP1TMPRSS4
SCHEMBL30867127 0.82 TSHR (0.54) CYP3A4TSHRMAPK1TDP1TMPRSS4
SCHEMBL29403188 0.82 TSHR (0.62) CYP3A4TSHRMAPK1TDP1TMPRSS4
SCHEMBL107751 0.82 TSHR (0.62) CYP3A4TSHRMAPK1TDP1TMPRSS4
SCHEMBL31303886 0.82 SLC6A4 (0.46) CYP3A4TSHRMAPK1TDP1RAB9A
SCHEMBL987352 0.82 IDO1 (0.50) CYP3A4TSHRMAPK1TDP1TMPRSS4
SCHEMBL29649700 0.82 IDO1 (0.50) CYP3A4TSHRMAPK1TDP1TMPRSS4
SCHEMBL657298 0.82 SLC6A4 (0.46) CYP3A4TSHRMAPK1TDP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-01-07 US disclosed
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 US disclosed
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-28 US disclosed
US-20200121678-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2020-04-23 US disclosed
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-05 US disclosed
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-28 US disclosed
US-9931340-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-03 US disclosed
EP-2748149-B9 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2017-11-15 EP disclosed
US-20170173007-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-22 US disclosed
US-9290456-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-03-22 US disclosed
CN-103748079-B Pyridazinone mixture and the purposes as DAAO inhibitor thereof TAKEDA PHARMACEUTICAL CO.,LTD. (JP) 2016-03-16 CN disclosed
EP-2748149-B1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-10-21 EP disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
EP-2748149-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2014-07-02 EP disclosed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
US-20020042541-A1 Process for producing bis( trifluoromethyl)benzaldehyde CENTRAL GLASS COMPANY, LIMITED (JP) 2002-04-11 US disclosed
EP-0384392-A1 Cyanation of haloaromatics utilizing catalysts generated in situ starting with NiCl2 or NiCl2 6H2O OCCIDENTAL CHEMICAL CORPORATION (US) 1990-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 CYP3A4 15/4885TSHR 831/4885MAPK1 3374/4885
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD CYP3A4 29/4885TSHR 1172/4885MAPK1 1645/4885
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD CYP3A4 29/4885TSHR 1172/4885MAPK1 1645/4885
US-20200121678-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD CYP3A4 29/4885TSHR 1172/4885MAPK1 1645/4885
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 CYP3A4 177/4885TSHR 1688/4885MAPK1 4726/4885
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD CYP3A4 29/4885TSHR 1172/4885MAPK1 1645/4885
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD CYP3A4 29/4885TSHR 1172/4885MAPK1 1645/4885
US-20020042541-A1 Process for producing bis( trifluoromethyl)benzaldehyde BRPF1, PFAS, FLI1 CYP3A4 1228/4885TSHR 3260/4885MAPK1 1046/4885
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD CYP3A4 29/4885TSHR 1172/4885MAPK1 1645/4885
US-20170173007-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD CYP3A4 29/4885TSHR 1172/4885MAPK1 1645/4885
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD CYP3A4 29/4885TSHR 1172/4885MAPK1 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.